Zurich Cantonal Bank
MAZE

Zurich Cantonal Bank’s Maze Therapeutics MAZE Stock Holding History

Zurich Cantonal Bank’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5K Buy
655
+294
+81% +$7.71K ﹤0.01% 2481
2026
Q1 		$10.8K Buy
+361
New +$15.9K ﹤0.01% 2481

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Zurich Cantonal Bank's MAZE Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Maze Therapeutics (MAZE) stake by 81% in Q2 2026, buying an estimated $7.71K and bringing the position to 655 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Zurich Cantonal Bank first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Zurich Cantonal Bank held 655 shares of Maze Therapeutics worth $19.5K as of Q2 2026.
  • Zurich Cantonal Bank bought 294 Maze Therapeutics shares in Q2 2026, an estimated $7.71K.
  • Maze Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2481 holding.
  • Zurich Cantonal Bank first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.